Performance and Safety of the PHENIX LIBERTY, a Medical Device for Electrostimulation and Biofeedback, in the Treatment of Pelvic Static Disorders in Women With Urinary Incontinence.
NCT ID: NCT05938855
Last Updated: 2024-12-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
30 participants
INTERVENTIONAL
2024-05-06
2024-12-06
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
• Does the use of the medical device in the treatment of pelvic static disorders lead to an improvement in urinary incontinence?
Participants will use the medical device, which provides electrical stimulation, biofeedback and pressure biofeedback to re-educate the pelvic floor muscles and improve urinary incontinence.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Urinary incontinence is a condition affecting many women in their adult lives. It is considered a public health problem, and has a high negative impact on patients' quality of life. Physiotherapy-based perineal rehabilitation is considered the first-line treatment for this condition. Treatments consist of pelvic floor muscle exercises (physiotherapy) with or without the use of other resources such as biofeedback, electrical electro-stimulation and vaginal cones.
In this context, the promoter wishes to carry out this study in order to reinforce the data currently available on the medical device PHENIX LIBERTY.
Design:
Prospective, interventional with non invasive and non burdensome procedure, non-comparative, multicenter, open-label study of a CE-marked medical device.
Intervention :
As part of this clinical investigation, the medical device under investigation is used in accordance with its usual use, and the patient's therapeutic procedure includes additional, non-invasive procedures. These additional procedures relate to the addition of an end-of-life visit and validated questionnaires assessing functional deficiencies and impact on daily life.
The care will be conduct as follow:
* 1 inclusion visit (V0) (from 1 say to 15 days prior the the first functional therapeutic re-education session)
* 10 sessions of functional therapeutic re-education, during which the PHENIX LIBERTY device may be used. Sessions performed at regular intervals according to a schedule drawn up by the physiotherapist (between 10 and 12 weeks)
* 1 end visit (V11), 1 week after the 10th session to complet questionnaires
In total, the patient will be followed 15 weeks maximum
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Standard of care plus additional questionaire
As part of this clinical investigation, the medical device under investigation is used in accordance with its usual use, and the patient's therapeutic procedure includes additional, non-invasive procedures. These additional procedures relate to the addition of an end-of-life visit and validated questionnaires assessing functional deficiencies and impact on daily life.
Electrical stimulation and biofeedback with the medical device Phenix Liberty
The patient will undergo 10 therapeutic functional re-education sessions, at regular intervals according to a schedule drawn up by the physiotherapist, during which the PHENIX LIBERTY device may be used.
The patients will complete questionnaires at the end of the care Overall, the functional perineal rehabilitation sessions will include muscle testing, electrostimulation and biofeedback.
The follow up will be conduct as follow :
* 10 sessions between 10 and 12 weeks
* 1 end visit, within the week after the 10th session
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Electrical stimulation and biofeedback with the medical device Phenix Liberty
The patient will undergo 10 therapeutic functional re-education sessions, at regular intervals according to a schedule drawn up by the physiotherapist, during which the PHENIX LIBERTY device may be used.
The patients will complete questionnaires at the end of the care Overall, the functional perineal rehabilitation sessions will include muscle testing, electrostimulation and biofeedback.
The follow up will be conduct as follow :
* 10 sessions between 10 and 12 weeks
* 1 end visit, within the week after the 10th session
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Adult patient (between 18 / 75 years old);
* Patient with at least one of the following symptoms related to a pelvic static disorder: pain, hypertonia, muscle weakness, decreased or loss of motor control, trophic abnormality;
* Patient who can make herself available to participate in the sessions regularly and who believes that she will be able to complete the tenth treatment session no later than 8 weeks after V0;
* Patient who has signed the consent form to participate in the study;
* Patient physically and mentally willing and able, in the judgment of the investigator at the time of recruitment, to perform the procedures under study;
* Patient with social protection.
Exclusion Criteria
* Patient with BMI ≥30 kg/m²
* Patient who has had more than 3 deliveries;
* Patient with stroke, Alzheimer's, multiple sclerosis, spinal cord involvement, narrow lumbar canal, cauda equina syndrome, or cognitive and/or behavioral impairment that may, in the practitioner's judgment, interact with the self-questionnaire or biofeedback assessment;
* Pregnant woman at the inclusion visit;
* Patient with an implanted pacemaker or spinal cord trainer;
* Patient with hypersensitivity to electrostimulation;
* Patient with such vaginal atrophy that an endovaginal probe cannot be used
* Patient with chronic or recurrent vaginal or urinary tract infection on long-term treatment;
* Patient with vaginal pathology (undiagnosed bleeding, cancer in the area to be treated);
* Patient who has renounced her liberty by administrative or judicial sentence, or who is under guardianship or limited judicial protection;
* Patient participating in an interventional clinical trial or testing/having tested an investigational drug and/or medical device within 30 days prior to inclusion in the study in relation to the relevant pathology;
* Patient who cannot read or write French;
* Patient refusing to participate in the study.
18 Years
75 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
CEISO
INDUSTRY
Human Physio
UNKNOWN
Pôle santé de la Nartassière
UNKNOWN
Vivaltis
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mathias Willame
Role: PRINCIPAL_INVESTIGATOR
Human Physio
Julie Perrin
Role: PRINCIPAL_INVESTIGATOR
Pôle santé de la Nartassière
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pôle santé de la Nartassière
Mouans-Sartoux, , France
Human Physio
Nîmes, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2023-A02195-40
Identifier Type: -
Identifier Source: org_study_id